{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["Colorectal Cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2630892"],"location":["Japan"],"study_start_month":["11"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study to examine efficacy prediction of Regorafenib with FDG-PET/CT in patients with treatment-refractory metastatic colorectal cancer","description":"Interventions: Regorafenib:160 mg orally, once daily for 3 weeks and one week rest in each cycle.\nPrimary outcome(s): Response rate in change of SUVmax in primary target lesion (the highest value in SUVmax at baseline) at 4 weeks after treatment by Regorafenib.\nStudy Design: Single arm Non-randomized","dates":{"creation":"2014-11-15"},"accession":"2630892","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000015563"]}}